Cornea - ARVO

ARVO 2013 Annual Meeting Abstracts by Scientific Section/Group - Cornearespectively. Subjects were instructed to instill 1 to 2 drops of theassigned study product in each eye as needed, but at least 2 timesdaily, for 30 days. The endpoints investigated were changes frombaseline in Ocular Surface Disease Index (OSDI), tear breakup time(TBUT) and ocular surface staining at the Day 30 visit, as well asadverse events, comfort and acceptability.Results: All groups showed improvement from baseline in OSDI atDay 30 (p1 year after bonemarrow transplantation. These patients tend to have severe symptomscoincident with extensive corneal epitheliopathy. However, Schirmerscores may vary significantly, and do not always correlate with otherdisease parameters, and thus should not be the principal diagnostic orprognostic parameter in assessing these patients.Commercial Relationships: Hasanain Shikari, None; Ujwala S.Saboo, None; Reza Dana, Allergan (C), Alcon (C), Bausch & Lomb(C), Eleven Bio (I), GSK (F), Novabay (C), Revision Optics (C),Novaliq (C), RIgel (F)Support: NIH-EY19098Program Number: 4332 Poster Board Number: C0070Presentation Time: 8:30 AM - 10:15 AMRelationships among Tear Film Stability, Tear Osmolarity,Corneal Staining History, and Dryness SymptomsThao N. Yeh 1 , Nina Tran 1 , Andrew D. Graham 1 , Harry M. Green 2 ,Meng C. Lin 1, 2 . 1 Clinical Research Center, School of Optometry,University of California, Berkeley, Berkeley, CA; 2 School ofOptometry, University of California, Berkeley, Berkeley, CA.Purpose: To explore the relationships among tear osmolarity, tearfilm stability, corneal staining history, and dryness symptoms in soft©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the ARVO Office at arvo@arvo.org.